Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of Surgical Methods on Resistant Sites in Stable Vitiligo Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03717025
Recruitment Status : Recruiting
First Posted : October 23, 2018
Last Update Posted : October 23, 2018
Sponsor:
Information provided by (Responsible Party):
Davinder Parsad, Postgraduate Institute of Medical Education and Research

Brief Summary:
Comparing the Efficacy of Three Different Surgical Methods on Resistant Sites in Stable Vitiligo.

Condition or disease Intervention/treatment Phase
Vitiligo Procedure: SUCTION BLISTER EPIDERMAL GRAFTING Procedure: MINI PUNCH GRAFTING Procedure: NON CULTURED EPIDERMAL CELL SUSPENSION Not Applicable

Detailed Description:

The treatment of vitiligo includes both medical and surgical modalities, whose goal is to restore melanocytes to the depigmented skin so that the epidermis restores back to normal morphology and functions. Although medical treatment is the main stay of treatment, it is not effective in all and residual lesions need augmented surgical treatment later for further completion of repigmentation.

Now a day surgical modalities have become treatment of choice for stable vitiligo not responding to medical treatment although there are numerous sites which do not respond that well to surgical procedure as well. The investigators ought to compare the efficacy of 3 well established surgical methods i.e. Mini Punch Grafting vs Suction Blister Epidermal Grafting vs Non Cultured Epidermal cell Suspension on stable vitiligo patches localized to acral areas and bony prominences like elbows, knees and ankles. Out of all the vitiligo patches in a given participant, 3 different patches on acral and bony areas will be chosen and participants will be treated with 3 different methods.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Comparative Study Between Autologous Mini Punch Grafting, Suction Blister Grafting and Non-Cutured Epidermal Cell Suspension on Resistant Sites in Stable Vitiligo
Actual Study Start Date : July 1, 2017
Estimated Primary Completion Date : October 2018
Estimated Study Completion Date : November 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Vitiligo

Arm Intervention/treatment
Active Comparator: Mini Punch Grafting Procedure: MINI PUNCH GRAFTING
  1. Recipient area is prepared first after shaving and cleaning with surgical spirit. 2 % lignocaine with or without adrenalin will be infiltrated as local aneasthetic.
  2. The punched out chambers are spaced at a gap of less than 5 mm (preferably 2 - 2.5 mm) from each other.
  3. The donor area is either upper lateral portion of thigh or gluteal region.
  4. Grafts are placed directly from donor to the recipient area. Care is taken, so that graft edges are not folded, the tissue is not crushed or placed upside down.
  5. Hemostasis is achieved by pressing a saline soaked gauze piece over the area.
  6. For the recipient area 3 layers of dressing from inside out are : paraffin embedded non adherent sterile gauze, sterile surgipad, and micropore.
  7. For the donor area only surgipad and micropore are used.
  8. Immobilisation of recipient area is advised along with antibiotics and analgesics till removal of dressing (after 4-7 days).

Active Comparator: Suction Blister Epidermal Grafting Procedure: SUCTION BLISTER EPIDERMAL GRAFTING
  1. Preferred donor sites for making blister is lateral aspect of upper thigh. The area is shaved and cleansed with surgical spirit.
  2. Blister formation is induced by using suction apparatus.
  3. Recipient site is surgically prepared by doing dermabrasion.
  4. After formation of blisters, each blister is gently cleansed with normal saline and cut all along its border with curved iris scissors parallel to the skin surface. The roof is everted over the thumb with dermal surface facing upwards and then with the help of blunt end of forceps it is placed on the recipient area.
  5. The graft is firmly pressed with sterile moist gauze to remove any underneath serous collection.
  6. The pressure dressing is done with double layer framycetin tulle, moist gauze and bandage.
  7. Donor area is dressed with dry sterile pads.
  8. The part is immobilized and Antibiotics and Analgesic are given till dressing are removed (after 5-7 days).

Active Comparator: Non Cultured Epidermal Cell Suspension Procedure: NON CULTURED EPIDERMAL CELL SUSPENSION
  1. About one-tenth the size of recipient area is selected as the donor site.
  2. Split thickness skin graft is taken under aseptic precautions with the help of a shaving blade held firmly by a straight artery forceps.
  3. The area is dressed with Bactigras gauze.
  4. Split thickness skin specimen is transferred under aseptic conditions to a container with Normal Saline and transferred to laboratory for preparing suspension.
  5. Recipient site is dermabraded under aseptic precautions until tiny pinpoint bleeding spots are seen.
  6. Epidermal cell suspension is carefully transferred to a tuberculin syringe.
  7. With 18 gauge needle attached to this syringe, suspension is spread evenly on dermabraded recipient site.
  8. This is then covered with Collagen dressing, followed by bactigras, guaze and tegaderm dressings from inside to outside.
  9. The patient is observed for 2 hours after performing the procedure and given antibiotics and analgesics for 5-7 days till dressing removal.




Primary Outcome Measures :
  1. Repigmentation At Surgery Site [ Time Frame: Repigmentation will be assessed at 12 weeks. ]

    To assess the difference in extent of repigmentation of the surgery site by three different methods at 12 weeks of post treatment follow up in a given patient.

    Repigmentation will be assessed as follows:

    ≤25% Minimal repigmentation 26-50% Mild repigmentation 51-75% Moderate repigmentation 76-90% Marked repigmentation >90% Excellent repigmentation



Secondary Outcome Measures :
  1. Color Matching of Repigmented Area [ Time Frame: Assessment at 12 weeks. ]
    Color matching of the repigmented area with the surrounding normal skin will be done in each case as 'somewhat lighter than', 'same as' or 'somewhat darker than' normal skin.

  2. Patient's Quality of Life Post Surgery [ Time Frame: Assessment at 12 weeks. ]
    Patient satisfaction will be assessed using Patient Global Assessment score.

  3. Patient's Quality of Life Post Surgery [ Time Frame: Assessment at 12 weeks. ]
    Quality of life assessement post procedure will be done using Vitiligo specific questionnaire.

  4. PATTERN OF REPIGMENTATION [ Time Frame: Assessment at 12 weeks. ]
    Pattern of repigmentation attained post-procedure will be noted as 'diffuse', 'perifollicular' or 'migrating from the borders'.

  5. ADVERSE EVENTS [ Time Frame: Assessment at 4, 8 and 12 weeks. ]
    Adverse events both at recipient and donor sites.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subjects with clinical diagnosis of focal, segmental or generalized vitiligo
  2. Patients with lesions of size > 1.5cm x 1cm present on acral areas and bony prominences.
  3. Vitiligo lesions has been stable for 1 year.
  4. Disease not responding to medical treatment, or there are residual patches (after medical therapy) of vitiligo which inturn are located on acral areas and bony prominences.
  5. Maximum size of vitiligo patches to be selected for surgery will not be >100cm2.

Exclusion Criteria:

  1. Age less than 18 years
  2. Pregnancy and lactation
  3. Patient with actively spreading vitiligo
  4. History of Koebnerisation
  5. History of hypertrophic scars or keloidal tendency
  6. Bleeding disorders
  7. Patients with unrealistic expectation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03717025


Locations
Layout table for location information
India
Post Graduate Institute of Medical Education and Research Recruiting
Chandigarh, India, 160012
Contact: MUTHU SENDHIL KUMARAN, ASSOCIATE PROFESSOR    9876930521 ext 91    drsen_2000@yahoo.com   
Contact: AMIT KUMAR, JUNIOR RESIDENT    7347638076 ext 91    amitdalla615@gmaiil.com   
Sponsors and Collaborators
Postgraduate Institute of Medical Education and Research

Layout table for additonal information
Responsible Party: Davinder Parsad, PROFESSOR, DEPARTMENT OF DERMATOLOGY, Postgraduate Institute of Medical Education and Research
ClinicalTrials.gov Identifier: NCT03717025     History of Changes
Other Study ID Numbers: INT/IEC/2017/1251
First Posted: October 23, 2018    Key Record Dates
Last Update Posted: October 23, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: Overall results of the study will be available to other researchers.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Davinder Parsad, Postgraduate Institute of Medical Education and Research:
ACRAL
Additional relevant MeSH terms:
Layout table for MeSH terms
Vitiligo
Hypopigmentation
Pigmentation Disorders
Skin Diseases